ELEV
- Elevation Oncology, Inc.
()
Overview
Company Summary
Elevation Oncology, Inc. is a biopharmaceutical company that focuses on discovering and developing precision medicines for patients suffering from rare forms of cancer. The company's primary objective is to address the unmet medical needs of individuals with specific genomic alterations that drive the growth and spread of their cancer.
Elevation Oncology's approach involves identifying and targeting specific genetic alterations known as NRG1 fusions, which occur in multiple types of solid tumors such as non-small cell lung cancer, pancreatic cancer, and breast cancer. These alterations lead to abnormal activation of a signaling pathway involved in cell growth and survival.
By developing precision therapies that target these NRG1 fusions, Elevation Oncology aims to offer personalized treatment options for patients who previously had limited or no effective options available. The company leverages its expertise in tumor genomics, drug discovery, and clinical development to provide hope to patients facing these rare and difficult-to-treat cancers.
Elevation Oncology conducts comprehensive research and clinical trials to assess the safety and efficacy of their therapies. With a patient-centric approach, the company aims to improve patients' quality of life by providing potential breakthrough treatments and collaborating with healthcare professionals and advocacy organizations.
In summary, Elevation Oncology is a biopharmaceutical company that specializes in developing precision medicines to target specific genetic alterations that drive the growth of rare forms of cancer. By focusing on the NRG1 fusions, the company aims to offer personalized treatment options for patients facing limited therapeutic choices.